News
VNRX
0.2113
-3.69%
-0.0081
Weekly Report: what happened at VNRX last week (0928-1002)?
Weekly Report · 5d ago
VolitionRx Consensus Price Target Decreased by 17.44% to $13.89
NASDAQ · 10/02 12:49
Weekly Report: what happened at VNRX last week (0921-0925)?
Weekly Report · 09/28 09:18
VolitionRx Uses Private Equity Issuance to Reduce Debt
TipRanks · 09/25 22:57
Weekly Report: what happened at VNRX last week (0914-0918)?
Weekly Report · 09/21 09:19
VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France
PR Newswire · 09/17 13:17
VolitionRx Launches DETECSEPS Sepsis Detection Project With ~$7.3M French Government Funding
Benzinga · 09/17 12:19
VolitionRx Participates in Launch of DETECSEPS Program in France
PR Newswire · 09/17 12:17
VolitionRx Reduces Debt Through Convertible Note Share Issuance
TipRanks · 09/15 21:54
VolitionRx prepays $7.5M senior secured convertible note in full
Seeking Alpha · 09/14 12:58
VolitionRx Fully Pays Off $7.5M Convertible Promissory Note, Dated May 20, 2025
Benzinga · 09/14 12:20
Weekly Report: what happened at VNRX last week (0907-0911)?
Weekly Report · 09/14 09:19
VolitionRx presents early stage I solid cancer detection at ESMO MAP Conference
TipRanks · 09/10 12:26
Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference
PR Newswire · 09/10 12:17
Weekly Report: what happened at VNRX last week (0831-0904)?
Weekly Report · 09/07 09:18
VolitionRx Gains Flexibility With New ATM Waiver Agreement
TipRanks · 09/02 22:04
VolitionRx Issues Shares to Convert Senior Debt
TipRanks · 09/02 10:30
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 08/31 12:06
Weekly Report: what happened at VNRX last week (0824-0828)?
Weekly Report · 08/31 09:20
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 08/28 21:06
More
Webull provides a variety of real-time VNRX stock news. You can receive the latest news about Volitionrx through multiple platforms. This information may help you make smarter investment decisions.
About VNRX
VolitionRx Limited is a company focused on advancing the science of epigenetics. The Company is focused on saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its products are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.